Navigation Links
Humanized mice may provide clues to better prevent and treat typhoid fever
Date:9/22/2010

mon. It also requires multiple doses. Studies in travelers suggest that many fail to take the vaccine properly.

Most of what scientists know about how Salmonella causes disease comes from studying a strain called Salmonella typhimurium, which can infect both mice and humans.

However, Fang noted that Salmonella infections in mice have not been found to correlate well with human typhoid infections.

"The mouse Salmonella infection differs from human typhoid in a number of important respects," he said. Immunity to one strain is fundamentally distinct from immunity to the other. This complicates attempts to construct vaccines based on observations of mice infected with Salmonella typhimurium."

Fang added that Salmonella typhi, the cause of human typhoid fever, is highly adapted to people. It has evolved many ways to evade infection-fighting defenses inside humans. It can also enter and destroy disease-fighting cells. The bacteria induce inflammation where it is in their own self-interest, and suppress it when and where it might be a disadvantage, such as in the intestine. Salmonella has changed over time by acquiring new DNA, such as plasmids and bacteriophages, from other organisms. This borrowed DNA makes it more virulent to humans and other animal hosts.

The host-pathogen interactions in mouse typhoid and human typhoid fever are drastically removed from each other, Fang said.

The researchers demonstrated that human blood-forming cells engrafted into immune-deficient mice allowed the mice to be infected with the organism that causes human typhoid fever, and that the typhoid bacteria appeared to reproduce inside the human cells. The researchers were also able to use this model to look for genetic factors that the typhoid bacteria need to cause severe illness.

Based on their studies, the researchers believe that the new lab mouse model can provide an unprecedented opportunity to gain insights into how the human t
'/>"/>

Contact: Leila Gray
leilag@u.washington.edu
206-685-0381
University of Washington
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Rotating high-pressure sodium lamps provide flowering plants for spring markets
2. New insights provide promise for development of tools to protect damaged tissues
3. Hair provides proof of the link between chronic stress and heart attack
4. LSUHSC pediatric weight expert provides obesity trinity answers
5. Special edition journal provides new perspectives and guidance for managing white pine blister rust
6. Huntingtons disease discovery provides new hope for treatment
7. Mother Nature to provide an environmentally friendly method for reducing mosquitoes
8. Aware Biometrics Software Provided for Large Federal Agencys PIV Credentialing System
9. Flemish researchers provide the first experimental evidence of dynamic allostery in protein regulation
10. World-renowned authorities provide current perspectives on Darwins theory of evolution
11. De La Rue Provides Second-Generation ePassport for Malta
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Humanized mice may provide clues to better prevent and treat typhoid fever
(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
(Date:4/8/2015)... CHARLOTTE, N.C. , April 8, 2015 /PRNewswire/ ... technology solutions and services, and Morpho, a leading ... in partnership to produce the market,s most advanced ... Infinisource,s iSolved NXG time clock is setting ... attendance and labor data for the small and ...
(Date:4/2/2015)... , April 2, 2015 Fingerprint ... fingerprint sensor FPC1025 from the distributor World Peace Industrial ... during Q2 2015 although the major part of the ... will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... 30 to 40 million years ago, grasses on Earth underwent ... of atmospheric carbon dioxide by engineering an internal mechanism to ... in a car, could more efficiently convert sunlight and nutrients ... disputed. They dominate in hot, tropical climes and now make ...
... the senses. Tragically, it commonly strikes in early childhood, severely ... In many cases, children gradually lose their hearing to ... years, but scientists know very little about how this progressive ... Over half the cases of childhood deafness are estimated to ...
... PHILADELPHIA Consuming two or more soft drinks per ... twofold compared to individuals who did not consume soft drinks, ... Prevention , a journal of the American Association for Cancer ... of the most deadly, and only 5 percent of people ...
Cached Biology News:Brown biologist solves mystery of tropical grasses' origin 2Brown biologist solves mystery of tropical grasses' origin 3Mice shed new light on causes of childhood deafness 2Soft drink consumption may increase risk of pancreatic cancer 2
(Date:4/27/2015)... BRUNSWICK, New Jersey , 27 ... société de découverte médicamenteuse spécialisée dans ... antibiotiques destinés à soigner les infections ... aujourd,hui la présentation de données prouvant ... majeur, le TXA709, dans la lutte ...
(Date:4/27/2015)... , April 27, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today provided commentary on clinical study data ... a poster session at the American Association for ... ADXS31-164 is a novel Lm -LLO immunotherapy ...
(Date:4/27/2015)...  Haemonetics Corporation (NYSE: HAE ) today ... of $226.5 million, down 6%.  Excluding currency impact, ... Company reported a fourth quarter GAAP net loss ... net income, exclusive of transformation, restructuring and deal ... 1%, and adjusted earnings per share were $0.47, ...
(Date:4/27/2015)... Texas (PRWEB) April 27, 2015 ... for use in applications such as animal waste ... and oil reduction in wastewater treatment plants and ... an exhibitor at the Texas Commission on Environmental ... 5-6 in Austin, Texas. , The company will ...
Breaking Biology Technology:TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 3Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 4Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 7Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 8Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 9Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 10Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 11Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 12Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 13Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 14Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 15Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 16Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 17Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 18Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 19Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 20Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 21Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 22Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 23Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 24Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 25Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 26Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 27Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 28Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 29Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 30
... today announced the release of a product that will allow ... perhaps improve the cost effectiveness of drug discovery. , ,The ... of the company's existing PreserveX line, and it was launched ... Japan in Kyoto, Japan. CEO Ralph Kauten said the latest ...
... which provides software and services to the financial and ... up 13 percent to $1.1 billion. , ,Net income ... the company made in the first quarter of 2005 ... the first quarter included repurchasing 5.4 million shares of ...
... agreements needed for AT&T to move forward on its deployment ... all this redeployment, AT&T should be setting its sights higher ... DSL is shortsighted. , ,The marketing strategy of Project Lightspeed ... to provide more services in a true broadband package. Instead, ...
Cached Biology Technology:AT&T should set sights higher than repackaging DSL with Project Lightspeed 2AT&T should set sights higher than repackaging DSL with Project Lightspeed 3AT&T should set sights higher than repackaging DSL with Project Lightspeed 4AT&T should set sights higher than repackaging DSL with Project Lightspeed 5AT&T should set sights higher than repackaging DSL with Project Lightspeed 6
Human Serum FDA Licensed US Donor Centers Sterile / Non-sterile: Sterile Filtered to 0.2 micron Information: Extensive Viral Testing ...
Normal human AB serum, pooled...
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Biology Products: